Pharmaceutical giant Novo Nordisk is to take over German biotech company Cardior Pharmaceuticals in a deal worth up to €1.025 billion. The latter, which works mainly on cardiovascular cures, will lay the foundation for Novo Nordisk to expand into the heart disease sector. Novo Nordisk, of weight loss drug Wegovy and diabetes drug Ozempic fame, recently became Europe’s biggest company, with a market capitalisation of about DKK 3.05 trillion (€0.41 trillion). The company also accounts for almost 50% of global insulin production. At the time of writing, the company’s shares were trading at around…